Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Relay Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLAY | Benzinga
Relay Therapeutics Inc has a consensus price target of $20.3 based on the ratings of 11 analysts. The high is $29 issued by Raymond James on April 19, 2023. The low is $16 issued by HC Wainwright & Co. on March 7, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Goldman Sachs, and Stifel on March 7, 2025, February 27, 2025, and February 27, 2025, respectively. With an average price target of $19 between HC Wainwright & Co., Goldman Sachs, and Stifel, there's an implied 660.00% upside for Relay Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Stifel
JMP Securities
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Relay Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 540% | HC Wainwright & Co. | Robert Burns9% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 620% | Goldman Sachs | Salveen Richter53% | $20 → $18 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 820% | Stifel | Bradley Canino22% | $27 → $23 | Maintains | Buy | Get Alert |
| 01/14/2025 | Buy Now | 540% | HC Wainwright & Co. | Robert Burns9% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 740% | JMP Securities | Silvan Tuerkcan53% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | 620% | Leerink Partners | Christopher Liu48% | $19 → $18 | Maintains | Outperform | Get Alert |
| 12/04/2024 | Buy Now | 540% | HC Wainwright & Co. | Robert Burns9% | $20 → $16 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 700% | HC Wainwright & Co. | Robert Burns9% | $19 → $20 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | 660% | HC Wainwright & Co. | Robert Burns9% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 740% | JMP Securities | Silvan Tuerkcan53% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 1020% | Stifel | Bradley Canino22% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 660% | HC Wainwright & Co. | Robert Burns9% | $18 → $19 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 860% | B of A Securities | Jason Gerberry63% | $20 → $24 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 740% | JP Morgan | Eric Joseph37% | $23 → $21 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 580% | Barclays | Peter Lawson41% | $14 → $17 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 700% | Goldman Sachs | Salveen Richter53% | → $20 | Reinstates | → Buy | Get Alert |
| 09/10/2024 | Buy Now | 540% | Jefferies | Akash Tewari39% | $10.6 → $16 | Upgrade | Hold → Buy | Get Alert |
| 09/10/2024 | Buy Now | — | Oppenheimer | Matthew Biegler33% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/07/2024 | Buy Now | 820% | JP Morgan | Eric Joseph37% | $29 → $23 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 860% | Oppenheimer | Matthew Biegler33% | $25 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2024 | Buy Now | 460% | Barclays | Peter Lawson41% | $15 → $14 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 740% | JMP Securities | Silvan Tuerkcan53% | $24 → $21 | Maintains | Market Outperform | Get Alert |
| 07/17/2024 | Buy Now | 620% | HC Wainwright & Co. | Robert Burns9% | $20 → $18 | Maintains | Buy | Get Alert |
| 06/07/2024 | Buy Now | 700% | HC Wainwright & Co. | Robert Burns9% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 500% | Barclays | Peter Lawson41% | $15 → $15 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/06/2024 | Buy Now | 860% | JMP Securities | Silvan Tuerkcan53% | $24 → $24 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/06/2024 | Buy Now | 900% | Oppenheimer | Matthew Biegler33% | $33 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 1100% | Stifel | Bradley Canino22% | $25 → $30 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 580% | HC Wainwright & Co. | Robert Burns9% | $19 → $17 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 660% | HC Wainwright & Co. | Robert Burns9% | $33 → $19 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 1220% | HC Wainwright & Co. | Robert Burns9% | $30 → $33 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 1100% | HC Wainwright & Co. | Robert Burns9% | $32 → $30 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 1220% | Oppenheimer | Matthew Biegler33% | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 06/09/2023 | Buy Now | 1180% | HC Wainwright & Co. | Robert Burns9% | $46 → $32 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 860% | JMP Securities | Silvan Tuerkcan53% | $28 → $24 | Maintains | Market Outperform | Get Alert |
| 04/20/2023 | Buy Now | 400% | Jefferies | Akash Tewari39% | $16 → $12.5 | Upgrade | Underperform → Hold | Get Alert |
| 04/20/2023 | Buy Now | 1260% | Stifel | Bradley Canino22% | $38 → $34 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 1060% | JP Morgan | Eric Joseph37% | $42 → $29 | Maintains | Overweight | Get Alert |
| 04/19/2023 | Buy Now | 1020% | JMP Securities | Silvan Tuerkcan53% | → $28 | Reiterates | → Market Outperform | Get Alert |
| 04/19/2023 | Buy Now | 1060% | Raymond James | Dane Leone46% | → $29 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/19/2023 | Buy Now | 500% | Barclays | Peter Lawson41% | $23 → $15 | Maintains | Equal-Weight | Get Alert |
| 04/18/2023 | Buy Now | 1220% | Oppenheimer | Matthew Biegler33% | → $33 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 1060% | Raymond James | Dane Leone46% | → $29 | Initiates | → Outperform | Get Alert |
| 04/05/2023 | Buy Now | 1580% | JP Morgan | Eric Joseph37% | $45 → $42 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 1740% | HC Wainwright & Co. | Robert Burns9% | $43 → $46 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 1220% | Oppenheimer | Matthew Biegler33% | → $33 | Initiates | → Outperform | Get Alert |
| 01/19/2023 | Buy Now | 1020% | JMP Securities | Silvan Tuerkcan53% | $38 → $28 | Maintains | Market Outperform | Get Alert |
| 11/07/2022 | Buy Now | 1620% | HC Wainwright & Co. | Robert Burns9% | $50 → $43 | Maintains | Buy | Get Alert |
| 09/30/2022 | Buy Now | 820% | Barclays | Peter Lawson41% | → $23 | Initiates | → Equal-Weight | Get Alert |
| 09/14/2022 | Buy Now | 1420% | JMP Securities | Silvan Tuerkcan53% | $35 → $38 | Maintains | Market Outperform | Get Alert |
| 09/12/2022 | Buy Now | 1900% | HC Wainwright & Co. | Robert Burns9% | $46 → $50 | Maintains | Buy | Get Alert |
| 09/02/2022 | Buy Now | 1500% | Stifel | Bradley Canino22% | → $40 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 1740% | HC Wainwright & Co. | Robert Burns9% | $47 → $46 | Maintains | Buy | Get Alert |
| 06/06/2022 | Buy Now | 420% | Jefferies | Akash Tewari39% | → $13 | Initiates | → Underperform | Get Alert |
| 05/24/2022 | Buy Now | 1580% | Goldman Sachs | Salveen Richter53% | $49 → $42 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 1780% | HC Wainwright & Co. | Robert Burns9% | $54 → $47 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 1300% | JMP Securities | Silvan Tuerkcan53% | $50 → $35 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Relay Therapeutics (RLAY) stock?
The latest price target for Relay Therapeutics (NASDAQ:RLAY) was reported by HC Wainwright & Co. on March 7, 2025. The analyst firm set a price target for $16.00 expecting RLAY to rise to within 12 months (a possible 540.00% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
The latest analyst rating for Relay Therapeutics (NASDAQ:RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics reiterated their buy rating.
When was the last upgrade for Relay Therapeutics (RLAY)?
The last upgrade for Relay Therapeutics Inc happened on September 10, 2024 when Jefferies raised their price target to $16. Jefferies previously had a hold for Relay Therapeutics Inc.
When was the last downgrade for Relay Therapeutics (RLAY)?
The last downgrade for Relay Therapeutics Inc happened on September 10, 2024 when Oppenheimer changed their price target from N/A to N/A for Relay Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a reiterated with a price target of $16.00 to $16.00. The current price Relay Therapeutics (RLAY) is trading at is $2.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.